CCM
LABD icon

Capstone Capital Management’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Capstone Capital Management’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$388K Sell
50,261
-50,063
-50% -$674K 0.17% 140
2026
Q1 		$1.64M Buy
+100,324
New +$1.9M 1.65% 16

Other funds holding LABD

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Capstone Capital Management's LABD Position: Q2 2026 in Review

Capstone Capital Management reduced its Direxion Daily S&P Biotech Bear 3X ETF (LABD) stake by 50% in Q2 2026, selling an estimated $674K and leaving 50,261 shares worth $388K. The position accounts for 0.17% of the portfolio, ranked #140.

Capstone Capital Management first reported a position in LABD in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.64M in Q1 2026. 21 funds tracked by Wall St. Rank hold LABD as of Q2 2026.

  • Capstone Capital Management held 50,261 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $388K as of Q2 2026.
  • Capstone Capital Management sold 50,063 Direxion Daily S&P Biotech Bear 3X ETF shares in Q2 2026, an estimated $674K.
  • Direxion Daily S&P Biotech Bear 3X ETF made up 0.17% of Capstone Capital Management's portfolio in Q2 2026, its #140 holding.
  • Capstone Capital Management first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q1 2026 and has held it in 2 quarters since.
  • Capstone Capital Management's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $1.64M in Q1 2026.
  • 21 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q2 2026.

Based on Capstone Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.